
The 142nd iCeMS SEMINAR

Thu 24 Oct 2013
10:00-12:00

Venue:
2nd Floor Seminar Room (#A207)
iCeMS Main Building (#70), Kyoto University

<Part 1: 10:10-10:40>

Dr. Tsuneaki Sakata

Head, Innovation Design Office, Global Development, Shionogi & Co., Ltd.

**“Shionogi Science Program:
an industry-academic initiative for open innovation
in pharmaceutical industry”**

<Part 2: 10:40-11:10>

Dr. Sotirios Karathanasis

Executive Director, Strategy and Externalization Cardiovascular
and Gastrointestinal Research Area AstraZeneca

**“Industry-Academia Collaborations:
Current Trends and Issues to Overcome”**

<Part 3: 11:10-11:40>

Dr. Stephen Minger


Chief Scientist, Cellular Sciences, Life Sciences, GE Healthcare

**“Innovating Preclinical Drug Development
& Human Cell Therapy”**

Registration required. Register by Tue 15 October at:

http://www.kyoto-smi.org/innovation_support/other_seminar

Contact: Takashi Asada at tasada@icems.kyoto-u.ac.jp
Hosted by: iCeMS (Institute for Integrated Cell-Material Sciences), Kyoto University
Co-hosted by: NPO Kyoto SMI



The 142nd iCeMS SEMINAR

Abstracts for October 24 iCeMS Seminar

Dr. Tsuneaki Sakata <Part 1: 10:10-10:40>

Shionogi has a long history of building partnerships and collaborating with researchers in areas of interest and unmet medical need. As part of this wider goal, the Shionogi Science Program (SSP) was launched in the UK in 2011 following the success of the Japanese initiative FINDS (PHarma-INnovation Discovery competition Shionogi) which was founded in 2007.

Dr. Sotirios Karathanasis <Part 2: 10:40-11:10>

Although a variety of factors contribute to the productivity decline of the Pharmaceutical Industry (Pharma) in recent years, the declining ability to innovate is thought to play a fundamental role. This, so called “innovation deficit”, occurs in the background of an accelerated pace of innovation in Academia. Dr. Karathanasis will discuss possible factors responsible for this “innovation deficit” in Pharma, focusing on elements that might prevent Academic innovations from effective translocation, internalization, and translation into new drug Discovery and Development projects in Pharma. Finally, he will overview current models for Industry-Academia collaborations and discuss issues to overcome.

Dr. Stephen Minger <Part 3: 11:10-11:40>

The isolation of tissue-specific, multipotent stem cells from adult organs and the derivation of pluripotent human embryonic stem cells offer the potential for regeneration of a number of different tissues and organs susceptible to age-related degenerative conditions and traumatic injury. In the not-too-distant future, it will be possible to repair heart tissue damaged by myocardial infarction, to replace neuronal cells lost in Parkinson's and Alzheimer's diseases, to transplant new insulin producing cells for diabetics and myelinating cells for individuals afflicted with multiple sclerosis, and to replace bone and cartilage lost through aging and inflammatory disease.

Registration required. Register by Tue 15 October at:

http://www.kyoto-smi.org/innovation_support/other_seminar

Contact: Takashi Asada at tasada@icems.kyoto-u.ac.jp

Hosted by: iCeMS (Institute for Integrated Cell-Material Sciences), Kyoto University

Co-hosted by: NPO Kyoto SMI

